Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10
This article was originally published in The Pink Sheet Daily
Executive Summary
The Indian company has captured over half of the rituximab segment in the local market, earning close to $6 million in just over a year's time after launch of Rituxan generic Reditux.